da Cunha Marisa Gonzaga, Sigrist Rosa
Department of Dermatology Faculdade de Medicina do ABC Santo André São Paulo Brazil.
Institute of Radiology Hospital das Clínicas da Faculdade de Medicina da USP São Paulo São Paulo Brazil.
Skin Health Dis. 2022 Aug 19;3(1):e155. doi: 10.1002/ski2.155. eCollection 2023 Feb.
All the changes the skin goes through, peaking at flaccidity, occur in the dermis and hypodermis, leading to loss of support and a lower capacity to totally accommodate displacements or any loss of subjacent volume, bringing about the onset of furrows and sagging. Improvements in facial sagging may be obtained with the administrations of substances like poly-L-lactic acid (PLLA), which triggers a tissue response through a controlled inflammatory reaction.
Compare the tissue distribution of the particles of PLLA of both products available in Brazil (Sculptra® and Rennova Elleva®) during and immediately after their subdermal administrations, with 22G cannulas, through high-resolution ultrasound imaging.
A total of four patients aged between 18 and 64 years had the inner part of the upper arms divided into eight quadrants and treated with 16 ml of each product, reconstituted to correspond to 9.5 mg/ml. The sites where PLLA was injected were analyzed through the high-resolution ultrasound during (dynamic imaging) and immediately after the procedures (static imaging).
During Sculptra® injection, high-resolution ultrasound revealed that its distribution did not follow the trajectory of the cannula homogeneously. It was characterized by a more hyperechogenic central portion and an anechogenic peripheral portion, forming discrete posterior acoustic shadowing at times. Regarding Rennova ELLEVA® injection, the high-resolution ultrasound analysis showed a homogeneous distribution of the product across the subcutaneous tissue following the trajectory of the cannula without formation of significant interface with the surrounding tissue, maintaining the sonographic aspect of thinly granulated hyperechogenic deposits, with strong posterior acoustic shadowing during and immediately after its administration.
Static and dynamic high-resolution ultrasound imaging show a more homogenous distribution of PLLA particles with the use of Rennova ELLEVA® when compared with Sculptra®, which may induce the formation of capsules and a subsequent more dispersed fibroplasia, with larger area of action and a possible better therapeutic result. The interest of this article lies in its originality, highlighting the differences in the tissue distribution of two different brands of PLLA particles, which can impact the clinical response to the two products - which we are researching and seems to interfere with the increase in dermal thickness.
皮肤经历的所有变化,在松弛时达到顶峰,都发生在真皮和皮下组织中,导致支撑力丧失,完全容纳位移或下方任何体积损失的能力降低,从而引发皱纹和松弛。通过使用聚左旋乳酸(PLLA)等物质进行给药,可以改善面部松弛,PLLA通过可控的炎症反应引发组织反应。
通过高分辨率超声成像,比较巴西市场上两种产品(Sculptra®和Rennova Elleva®)在皮下给药期间及给药后立即使用22G套管针时PLLA颗粒的组织分布情况。
共有4名年龄在18至64岁之间的患者,将上臂内侧分为8个象限,每种产品各注射16毫升,重新配置后浓度为9.5毫克/毫升。通过高分辨率超声在注射过程中(动态成像)和注射后立即(静态成像)对注射PLLA的部位进行分析。
在注射Sculptra®期间,高分辨率超声显示其分布并非均匀地沿着套管针的轨迹。其特征是中央部分回声增强,周边部分无回声,有时会形成离散的后方声影。关于注射Rennova ELLEVA®,高分辨率超声分析显示该产品沿着套管针轨迹在皮下组织中均匀分布,与周围组织未形成明显界面,在给药期间及给药后立即保持细颗粒状高回声沉积物的超声表现,并伴有强烈的后方声影。
与Sculptra®相比,静态和动态高分辨率超声成像显示使用Rennova ELLEVA®时PLLA颗粒分布更均匀,Sculptra®可能会诱导胶囊形成及随后更分散的纤维增生,作用面积更大,可能产生更好的治疗效果。本文的价值在于其原创性,突出了两种不同品牌PLLA颗粒在组织分布上的差异,这可能会影响对这两种产品的临床反应——我们正在进行研究,且似乎会干扰真皮厚度的增加。